{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:34:42Z","timestamp":1794123282922,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.autrev.2015.01.011","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T04:01:34Z","timestamp":1421899294000},"page":"503-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"title":["Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice"],"prefix":"10.1016","volume":"14","author":[{"given":"Fabrizio","family":"Cantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Garlaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sanduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Conversano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.01.011_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","author":"Arkema","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients on biologic therapy: the international recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0020","first-page":"620","article-title":"Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy","volume":"137","author":"Beglinger","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2015.01.011_bb0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2015.01.011_bb0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"RR-17","key":"10.1016\/j.autrev.2015.01.011_bb0035","first-page":"1","article-title":"CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings","volume":"54","author":"Jensen","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.autrev.2015.01.011_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.140099","article-title":"Performance of the tuberculin skin test and interferon-\u03b3 release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches","volume":"91","author":"Goletti","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.140100","article-title":"Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review","volume":"91","author":"Piccazzo","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3899\/jrheum.140105","article-title":"Current treatment options for latent tuberculosis infection","volume":"91","author":"Bocchino","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"issue":"43","key":"10.1016\/j.autrev.2015.01.011_bb0060","doi-asserted-by":"crossref","DOI":"10.2807\/ese.14.43.19373-en","article-title":"Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers","volume":"14","author":"Girardi","year":"2009","journal-title":"Euro Surveill"},{"key":"10.1016\/j.autrev.2015.01.011_bb0065","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3899\/jrheum.130303","article-title":"Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-\u03b3 release assay results","volume":"40","author":"Costantino","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0070","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","article-title":"Risk assessment of tuberculosis in immunocompromised patients. A TBNET study","volume":"190","author":"Sester","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2015.01.011_bb0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/00365548.2014.938691","article-title":"Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay","volume":"46","author":"Kim","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0080","doi-asserted-by":"crossref","first-page":"e97366","DOI":"10.1371\/journal.pone.0097366","article-title":"Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants","volume":"9","author":"O'Shea","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2015.01.011_bb0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1183\/09031936.00079310","article-title":"Treatment of latent infection with Mycobacterium tuberculosis: update 2010","volume":"37","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2015.01.011_bb0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1183\/09031936.00033010","article-title":"Treatment of tuberculosis: update 2010","volume":"37","author":"Yew","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2015.01.011_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1465-9921-8-5","article-title":"Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study","volume":"8","author":"Goletti","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2015.01.011_bb0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lo Bue","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2015.01.011_bb0105","first-page":"1736","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0110","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2015.01.011_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-11-97","article-title":"Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies","volume":"4","author":"Ramagopalan","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2015.01.011_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"American Academy of Dermatology Work Group","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0135","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0140","first-page":"775","article-title":"Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy","volume":"31","author":"Cline","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2015.01.011_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.01.011_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.autrev.2012.05.009","article-title":"Biologic registries in rheumatology: lessons learned and expectations for the future","volume":"12","author":"Elkayam","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9914","key":"10.1016\/j.autrev.2015.01.011_bb0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.01.011_bb0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0180","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1136\/annrheumdis-2013-203695","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","volume":"73","author":"Keystone","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0185","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.120584","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2years of the GO-FORWARD study extension","volume":"40","author":"Keystone","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0190","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/acr.22072","volume":"65","author":"Emery","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0195","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/annrheumdis-2013-203742","volume":"73","author":"Weinblatt","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0200","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0205","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.autrev.2014.02.004","article-title":"The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.01.011_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.autrev.2015.01.011_bb0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0225","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.22314","article-title":"Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry","volume":"66","author":"Payet","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0230","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"9877","key":"10.1016\/j.autrev.2015.01.011_bb0240","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.01.011_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0250","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/acr.22110","article-title":"Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0260","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0265","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10067-013-2392-2","article-title":"Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity","volume":"33","author":"Takahashi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2474-15-14","article-title":"Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study","volume":"15","author":"N\u00fc\u00dflein","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2015.01.011_bb0280","first-page":"553","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"9894","key":"10.1016\/j.autrev.2015.01.011_bb0285","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.01.011_bb0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjd.12643","article-title":"One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis","volume":"170","author":"Reich","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.01.011_bb0295","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0300","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1073\/pnas.1121497109","article-title":"Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques","volume":"109","author":"Lin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.01.011_bb0305","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.01.011_bb0310","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","article-title":"Evaluation of the RABBIT Risk Score for serious infections","volume":"73","author":"Zink","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0315","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":"A six-month randomized, controlled, double-blind, dose\u2013response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.01.011_bb0320","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","article-title":"Bisphosphonates vs infliximab in ankylosing spondylitis treatment","volume":"53","author":"Viapiana","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.01.011_bb0325","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1183\/09031936.00203811","article-title":"European union standards for tuberculosis care","volume":"39","author":"Migliori","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2015.01.011_bb0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3899\/jrheum.140106","article-title":"Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2015.01.011_bb0335","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"Van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.01.011_bb0340","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.01.011_bb0345","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"10","key":"10.1016\/j.autrev.2015.01.011_bb0350","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","article-title":"British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-\u03b1 treatments","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2015.01.011_bb0355","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","article-title":"Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment","volume":"14","author":"Denis","year":"2008","journal-title":"Clin Microbiol Infect"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T06:12:47Z","timestamp":1651039967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1568997215000269"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.01.011","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}